Heart Failure Clinical Trial

Effects of Sacubitril/Valsartan on Subclinical Heart Failure in HIV (The ENCHANTMENT HIV Study)

Summary

Persons with HIV, even those well-treated, are at increased risk for heart disease when compared to the general population. Two hormones called aldosterone and brain natriuretic peptide (BNP), which have been shown to be abnormal in HIV, may be associated with inflammation as well as early changes in structure and function of the heart. This study is being conducted to evaluate whether therapies to block aldosterone and increase BNP levels may reduce the burden and progression of heart failure to improve cardiovascular health.

View Full Description

Full Description

This is a 6-month study enrolling persons with HIV with no known history of heart disease. Participants will be screened for early signs of heart failure using cardiac ultrasound (cardiac transthoracic echocardiography or cardiac TTE). Those participants who have early changes in the structure and function of the heart and may be at future risk for heart failure will be enrolled into the study. Additional imaging of the heart will occur using cardiac magnetic resonance imaging (cardiac MRI). Following baseline studies, participants will either receive a medication called sacubitril/valsartan or placebo for 6 months. Sacubitril/valsartan in an FDA approved medication currently being used for heart failure with reduced ejection fraction in the general population, and we are evaluating whether this medication could be useful to reduce HIV-related heart failure with preserved ejection fraction. Sacubitril/valsartan is an oral medication taken twice daily that may block aldosterone hormone and increase natriuretic peptide hormone. Overall, this study aims to investigate the effect of sacubitril/valsartan on measures of heart disease related to inflammation, structure and function of the heart muscle in HIV using cardiac TTE and cardiac MRI imaging as well as blood markers of heart failure and inflammation.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Antiretroviral therapy use for >12 months
HIV Viral Load <200 copies/mL
Left Ventricular Ejection Fraction>50%

Demonstration of one or more criteria for myocardial dysfunction on cardiac transthoracic echocardiogram, relevant to the progression of heart failure with preserved ejection fraction:

Left Atrial Volume Index > 28 mL/m2
Global Longitudinal Strain <18%
Left Ventricular Mass Index > 95g/m2 (female), 115 g/m2 (male)

Exclusion Criteria:

Known history of congestive heart failure or valvular disease
Recent cardiac event or stroke within 3 months
Current medication use acting along the RAAS pathway (ACEi, ARB, MR blockade, direct renin inhibitor), potassium (K) supplementation or diuretic
Angioedema to ACEi or ARB
SBP<100 mmHg
Medication suspected to have contraindication with active study drug
Steroid use within last 3 months
Uncontrolled diabetes requiring insulin and/or HbA1c > 7.5%
Creatinine (Cr)>1.5 mg/dL and estimated GFR<60 mL/min/1.73m2
K>5.5 mEq/L
Hemoglobin <10.0 g/dL
Known liver disease or ALT>3x upper limit normal
Pregnant, actively seeking pregnancy or breastfeeding
Estrogen, progestin derivative, or other sex steroid use within 3 months. Stable physiologic testosterone replacement (> 3 months) is acceptable
Current bacterial or other infection
Active substance abuse
Known reaction to gadolinium

Study is for people with:

Heart Failure

Phase:

Phase 2

Estimated Enrollment:

50

Study ID:

NCT04153136

Recruitment Status:

Recruiting

Sponsor:

Massachusetts General Hospital

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Massachusetts General Hospital
Boston Massachusetts, 02114, United States More Info
Suman Srinivasa, MD
Contact
617-726-1585
[email protected]
Allie Walpert, MSN
Contact
617-726-1696
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Heart Failure

Phase:

Phase 2

Estimated Enrollment:

50

Study ID:

NCT04153136

Recruitment Status:

Recruiting

Sponsor:


Massachusetts General Hospital

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider